Loading...
XNAS
SIBN
Market cap676mUSD
Aug 08, Last price  
15.68USD
1D
-3.92%
1Q
-15.20%
IPO
-25.33%
Name

SI-BONE Inc

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
4.05
EPS
—
Div Yield, %
—
Shrs. gr., 5y
10.91%
Rev. gr., 5y
19.96%
Revenues
167m
+20.37%
37,016,00048,999,00040,054,00041,173,00042,101,00047,983,00055,380,00067,301,00073,387,00090,152,000106,409,000138,886,000167,178,000
Net income
-31m
L-28.67%
-10,903,000-6,154,000-27,806,000-28,154,000-20,589,000-23,039,000-17,453,000-42,576,000-48,542,000-60,128,000-62,903,000-43,336,000-30,913,000
CFO
-12m
L-33.60%
-14,759,000-566,000-26,327,000-26,718,000-16,753,000-17,530,000-14,519,000-31,627,000-30,662,000-39,533,000-41,655,000-18,713,000-12,425,000

Profile

SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
URL
https://si-bone.com/
IPO date
Oct 17, 2018
Employees
357
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
167,178
20.37%
138,886
30.52%
106,409
18.03%
Cost of revenue
202,426
185,817
166,018
Unusual Expense (Income)
NOPBT
(35,248)
(46,931)
(59,609)
NOPBT Margin
Operating Taxes
1,647
Tax Rate
NOPAT
(35,248)
(46,931)
(61,256)
Net income
(30,913)
-28.67%
(43,336)
-31.11%
(62,903)
4.62%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,154
83,671
4,015
BB yield
-0.37%
-10.37%
-0.86%
Debt
Debt current
1,152
2,832
1,388
Long-term debt
3,789
40,503
42,301
Deferred revenue
Other long-term liabilities
34,583
18
30
Net debt
(145,101)
(122,684)
(53,601)
Cash flow
Cash from operating activities
(12,425)
(18,713)
(41,655)
CAPEX
(10,497)
(7,799)
(9,507)
Cash from investing activities
12,623
(59,798)
(2,815)
Cash from financing activities
1,958
90,933
2,197
FCF
(45,906)
(50,291)
(73,777)
Balance
Cash
150,042
166,019
97,290
Long term investments
Excess cash
141,683
159,075
91,970
Stockholders' equity
(431,106)
(400,102)
98,302
Invested Capital
635,563
609,903
45,792
ROIC
ROCE
EV
Common stock shares outstanding
41,467
38,427
34,202
Price
14.02
-33.21%
20.99
54.34%
13.60
-38.77%
Market cap
581,361
-27.92%
806,592
73.41%
465,145
-36.82%
EV
436,260
683,908
411,544
EBITDA
(36,309)
(41,503)
(56,157)
EV/EBITDA
Interest
3,440
3,462
2,819
Interest/NOPBT